Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.

RMD open·2026
Same author

Cystic fibrosis-associated inflammatory bowel disease: a case series and literature review.

Clinics and research in hepatology and gastroenterology·2026
Same author

Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives.

Expert opinion on biological therapy·2026
Same author

Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort.

RMD open·2026
Same author

Manual Insertion of Cochlear Implant Electrodes Versus Robot-Assisted Insertion and Analysis by Micro-CT: A Temporal Bone Study.

Audiology research·2026
Same author

Clonal Lymphocyte Expansions and JAK-STAT Pathway Mutations Define a Pathogenic Continuum Driving Resistance to Gluten-Free Diet in Celiac Disease.

Gastroenterology·2026

Related Experiment Video

Updated: Jul 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Navigating adalimumab biosimilars: an expert opinion.

Vered Abitbol1, Salim Benkhalifa2, Caroline Habauzit2

  • 1Service de gastroentérologie, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, 75014, France.

Journal of Comparative Effectiveness Research
|October 19, 2023
PubMed
Summary

The patent expiry of Humira® has led to multiple adalimumab biosimilars in Europe and the US. This article guides clinicians on selecting the best adalimumab biosimilar for immune and inflammatory conditions.

Keywords:
adalimumabbiosimilardevicedoseefficacyformulationnocebopatient expectationspatient–physician communicationsafety

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.3K

Related Experiment Videos

Last Updated: Jul 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.3K

Area of Science:

  • Immunology
  • Pharmacology
  • Drug Development

Background:

  • The patent expiry of Humira® (adalimumab) has resulted in the market entry of numerous adalimumab biosimilars in Europe and the USA.
  • These biosimilars are indicated for treating various immune and inflammatory conditions.

Purpose of the Study:

  • To explore the characteristics of available adalimumab biosimilars.
  • To assist clinicians in navigating treatment decisions among various adalimumab biosimilar options.
  • To highlight the importance of patient-physician communication regarding biosimilar prescribing.

Main Methods:

  • Review of product characteristics of adalimumab biosimilars.
  • Comparison of efficacy, safety, and immunogenicity data.
  • Analysis of differences in excipients, preservatives, and device types.

Main Results:

  • Adalimumab biosimilars demonstrate comparable efficacy, safety, and immunogenicity to the originator.
  • Key differences among biosimilars lie in excipients, preservatives, and device types.
  • Physician decision-making can be complex due to the array of available biosimilars.

Conclusions:

  • Adalimumab biosimilars offer viable treatment options for immune and inflammatory diseases.
  • Understanding biosimilar variations is crucial for effective clinical selection.
  • Open communication with patients is essential to manage expectations and mitigate potential nocebo effects.